FAQs Section Mobile IV therapy allows you to receive IV treatments at your home or office
Patient Counseling Information Patients must be informed that ADIPEX-P is a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity, and that coadministration of phentermine with other drugs for weight loss is not recommended [see Indications and Usage (1) and Warnings and Precautions (5)]
Continue supportive supplementation for at least 48 weeks post-cycle
Some patients achieve therapeutic weight loss at lower tirzepatide doses with minimal side effects, while others require dose escalation over weeks or months
Notably, weight reduction was dose-dependent and progressive, with participants continuing to lose weight throughout the study period, suggesting potential for even greater efficacy with extended treatment duration
Additional indications vary between drugs, with semaglutide approved for use in 12 years and above for weight management, while tirzepatide is approved for use in 10-year-olds and above for T2DM Both medications share similar gastrointestinal side effects, which leads many patients to discontinue use, as well as boxed warnings regarding the risk of thyroid tumors
